- Home
- MAIA vs SACH Comparison
MAIA vs SACH Comparison
Compare MAIA & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | SACH |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 48.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | MAIA | SACH |
|---|---|---|
| Price | $1.54 | $0.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 1.1M | 134.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 19.05% |
| EPS Growth | ★ 29.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.80 |
| 52 Week High | $3.19 | $1.35 |
Technical Indicators
Market Signals| Indicator | MAIA | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 29.76 |
| Support Level | $1.44 | N/A |
| Resistance Level | $1.52 | $1.12 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 12.86 | 0.06 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.